Corvidia Therapeutics

When Michael Davidson, CEO of NewAmsterdam Pharma, describes his company’s lead asset obicetrapib, he frames it as a solution to one of cardiology’s most persistent challenges: managing residual cardi

Novo Nordisk A/S has opened its bulging wallet to acquire Germany's Cardior Pharmaceuticals GmbH , boosting its cardiovascular pipeline through a deal worth up to €1.03bn. The Hannover-based biotech

With a star pipeline candidate entering Phase III clinical trials for the treatment for ulcerative colitis, Abivax S.A. is in the midst of a corporate rework to be able to secure funding and ultimat

With a stellar career in the pharmaceutical industry, including CEO roles for the last 12 years, Marc de Garidel could have been forgiven for putting his feet up for a while rather than taking the hel